​

Funding Round

Series A - Passage Bio

Series A - Passage Bio

Investment Firm

Overview

Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.

Announced Date

Feb 15, 2019

Funding Type

Series A

Highlights

Location

United States, North America

Social

Investor Lead

OrbiMed

OrbiMed

OrbiMed is a debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.

Participant Investors

6

Investor Name
Participant InvestorOrbiMed
Participant InvestorLilly Asia Ventures
Participant InvestorVersant Ventures
Participant InvestorFrazier Healthcare Partners
Participant InvestorVivo Capital

Round Details and Background

Passage Bio raised $115500000 on 2019-02-15 in Series A

Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Feb 15, 2019
Series A - Passage Bio
6-115.5M
Sep 04, 2019
Series B - Passage Bio
11-110.0M
Jan 21, 2021
Post-IPO Equity - Passage Bio
-154.0M

Recent Activity

There is no recent news or activity for this profile.